Therefore, the aim of this study was a comprehensive analysis of serum concentration and mRNA expression of galectins in patients with invasive breast cancer (BC).<h4>Methods</h4>Serum concentration of galectin-1, -2, -3, -4, -7, -8 and -9 in 60 women with invasive BC and 20 women with benign lesions were determined using the enzyme-linked immunosorbent assays (ELISA). The gene discussed is LGALS1; the disease is invasive breast carcinoma.